Comparative Analysis and in vitro Experiments of Signatures and Prognostic Value of Immune Checkpoint Genes in Colorectal Cancer

References

• Ciardiello D, Vitiello PP, Cardone C, et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat Rev. 2019;76:22–32. doi:10.1016/j.ctrv.2019.04.003
   PubMed Web of Science ®Google Scholar
• Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med. 2015;66(1):83–95. doi:10.1146/annurev-med-051513-102539
   PubMedGoogle Scholar
• Angell H, Galon J. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261–267. doi:10.1016/j.coi.2013.03.004
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945. doi:10.1038/nm.3909
   PubMed Web of Science ®Google Scholar
• Xu F, Jin T, Zhu Y, et al. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37(1):110. doi:10.1186/s13046-018-0777-4
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39. doi:10.1186/s13045-018-0582-8
   PubMed Web of Science ®Google Scholar
• Liu SS, Yang YZ, Jiang C, et al. Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients. J Transl Med. 2018;16(1):195. doi:10.1186/s12967-018-1570-z
   PubMedGoogle Scholar
• Raut CP, Pawlik TM, Rodriguez-Bigas MA. Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res. 2004;568(2):275–282. doi:10.1016/j.mrfmmm.2004.05.025
   PubMed Web of Science ®Google Scholar
• Hampel H, Frankel WL, Martin E, et al. Screening for the lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851–1860. doi:10.1056/NEJMoa043146
   PubMed Web of Science ®Google Scholar
• Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100(2):266. doi:10.1038/sj.bjc.6604867
   PubMed Web of Science ®Google Scholar
• Vilar E, Tabernero J. Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov. 2013;3(5):502–511. doi:10.1158/2159-8290.CD-12-0471
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. doi:10.1056/NEJMoa1500596
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration. OPDIVO (nivolumab) injection, for intravenous use. Package Insert. 2019. Accessed October 16, 2019.
   Google Scholar
• Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–779. doi:10.1200/JCO.2017.76.9901
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, Phase 2 study. Lancet Oncol. 2017;18(9):1182–1191. doi:10.1016/S1470-2045(17)30422-9
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X
   PubMed Web of Science ®Google Scholar
• Daud AI, Loo K, Pauli ML, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126(9):3447–3452. doi:10.1172/JCI87324
   PubMed Web of Science ®Google Scholar
• Inomata M, Kado T, Okazawa S, et al. Peripheral PD1-positive CD4 T-lymphocyte count can predict progression-free survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitor. Anticancer Res. 2019;39(12):6887–6893. doi:10.21873/anticanres.13908
   PubMed Web of Science ®Google Scholar
• Berntsson J, Eberhard J, Nodin B, et al. Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: relationship with sidedness and prognosis. Oncoimmunology. 2018;7(8):e1465165. doi:10.1080/2162402X.2018.1465165
   PubMed Web of Science ®Google Scholar
• Wang J, Sanmamed MF, Datar I, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG3. Cell. 2019;176(1–2):334–347.e12. doi:10.1016/j.cell.2018.11.010
   PubMed Web of Science ®Google Scholar
• ElTanbouly MA, Croteau W, Noelle RJ, et al. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity. Semin Immunol. 2019;42:101308. doi:10.1016/j.smim.2019.101308
   PubMed Web of Science ®Google Scholar
• Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(1):97–111. doi:10.1111/imr.12520
   PubMed Web of Science ®Google Scholar
• Huang RY, Francois A, McGray AR, et al. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cance. Oncoimmunology. 2017;6:e1249561. doi:10.1080/2162402X.2016.1249561
   PubMed Web of Science ®Google Scholar
• Danilova L, Ho WJ, Zhu Q, et al. Programmed Cell Death Ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival. Cancer Immunol Res. 2019;7(6):886–895. doi:10.1158/2326-6066.CIR-18-0822
   PubMed Web of Science ®Google Scholar
• Xu Z, Dai J, Wang D, et al. Assessment of tumor mutation burden calculation from gene panel sequencing data. Onco Targets Ther. 2019;12:3401–3409. doi:10.2147/OTT.S196638
   PubMed Web of Science ®Google Scholar
• Ma R, Xu L, Qu X, et al. AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status. Br J Cancer. 2018;118(11):1453–1463. doi:10.1038/s41416-018-0086-x
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501. doi:10.1056/NEJMc1713444
   PubMed Web of Science ®Google Scholar
• Li J, Lee Y, Li Y, et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8+ T cells. Immunity. 2018;48(4):773–786. doi:10.1016/j.immuni.2018.03.018
   PubMed Web of Science ®Google Scholar
• Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2016;20(3):123–137. doi:10.1016/j.blre.2005.10.001
   Google Scholar
• Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–510. doi:10.1038/ni1582
   PubMed Web of Science ®Google Scholar
• Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294(1–2):15–22. doi:10.1016/j.jim.2004.08.008
   PubMed Web of Science ®Google Scholar
• Lee JJ, Chu E. Recent advances in the clinical development of immune checkpoint blockade therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17(4):258–273. doi:10.1016/j.clcc.2018.06.004
   PubMed Web of Science ®Google Scholar
• Podojil JR, Miller SD. Potential targeting of B7-H4 for the treatment of cancer. Immunol Rev. 2017;276(1):40–51. doi:10.1111/imr.12530
   PubMed Web of Science ®Google Scholar
• MacGregor HL, Ohashi PS. Molecular pathways: evaluating the potential for B7-H4 as an immunoregulatory target. Clin Cancer Res. 2017;23(12):2934–2941. doi:10.1158/1078-0432.CCR-15-2440
   PubMed Web of Science ®Google Scholar
• Qiu ZC, Wu JY, Wang Y, et al. Expression and clinical significance of negative costimulatory molecules B7-H1, B7-H3 and B7-H4 in the process of colorectal cancer’s evolution. Transl Cancer Res. 2018;7(4):1026–1035. doi:10.21037/tcr.2018.07.15
   Web of Science ®Google Scholar
• Leung J, St-Onge P, Stagg J, et al. Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model. Cancer Immunol Immunother. 2017;66(4):491–502. doi:10.1007/s00262-016-1950-2
   PubMed Web of Science ®Google Scholar
• John P, Wei Y, Liu W, et al. The B7x immune checkpoint pathway: from discovery to clinical trial. Trends Pharmacol Sci. 2019;40(11):883–896. doi:10.1016/j.tips.2019.09.008
   PubMed Web of Science ®Google Scholar
• Tu L, Guan R, Yang H, et al. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival. Int J Cancer. 2020;147(2):12. doi:10.1002/ijc.32785
   Web of Science ®Google Scholar
• Yaghoubi N, Soltani A, Ghazvini K, et al. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:312–318. doi:10.1016/j.biopha.2018.11.105
   PubMed Web of Science ®Google Scholar
• Shen Z, Gu L, Mao D, et al. Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019;17(1):4. doi:10.1186/s12957-018-1544-x
   PubMedGoogle Scholar
• Wyss J, Dislich B, Koelzer VH, et al. Stromal PD-1/PD-L1 expression predicts outcome in colon cancer patients. Clin Colorectal Cancer. 2019;18(1):e20–e38. doi:10.1016/j.clcc.2018.09.007
   PubMed Web of Science ®Google Scholar
• Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148(1):77–87. doi:10.1053/j.gastro.2014.09.038
   PubMed Web of Science ®Google Scholar
• Emambux S, Tachon G, Junca A, et al. Results and challenges of immune checkpoint inhibitors in colorectal cancer. Expert Opin Biol Ther. 2018;18(5):561–573. doi:10.1080/14712598.2018.1445222
   PubMed Web of Science ®Google Scholar
• Giannakis M, Mu XJ, Shukla SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;17(4):1206. doi:10.1016/j.celrep.2016.10.009
   PubMed Web of Science ®Google Scholar
• Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, et al. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol. 2016;29(9):1104–1112. doi:10.1038/modpathol.2016.95
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610–618. doi:10.1200/JCO.2010.30.5425
   PubMed Web of Science ®Google Scholar
• Galon J, Pagès F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10(1):1. doi:10.1186/1479-5876-10-1
   PubMed Web of Science ®Google Scholar
• Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139. doi:10.1016/S0140-6736(18)30789-X
   PubMed Web of Science ®Google Scholar
• Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2965–2970. doi:10.1158/1055-9965.EPI-14-0654
   PubMed Web of Science ®Google Scholar
• McArdel SL, Terhorst C, Sharpe AH. Roles of CD48 in regulating immunity and tolerance. Clin Immunol. 2016;164:10–20. doi:10.1016/j.clim.2016.01.008
   PubMed Web of Science ®Google Scholar
• Wu Y, Kuang DM, Pan WD, et al. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology. 2013;57(3):1107–1116. doi:10.1002/hep.26192
   PubMed Web of Science ®Google Scholar
• Yuan YH, Chen J, Wang J, et al. Identification hub genes in colorectal cancer by integrating weighted gene co-expression network analysis and clinical validation in vivo and vitro. Front Oncol. 2020;10:638. doi:10.3389/fonc.2020.00638
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao H, Shi X, et al. Identification and validation of an immune-related gene signature predictive of overall survival in colon cancer. Aging. 2020;12(24):26095–26120. doi:10.18632/aging.202317
   PubMedGoogle Scholar
• Kitsou M, Ayiomamitis GD, Zaravinos A. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer. Int J Oncol. 2020;57(1):237–248. doi:10.3892/ijo.2020.5062
   PubMed Web of Science ®Google Scholar